首页> Cancer science> PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma.

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma.

导出 OA

翻译打印收藏纠错

第一作者： Noriko,Fukuhara

第一单位： Tohoku University Hospital, Sendai, Japan.

作者： Noriko,Fukuhara ^[1] ; Isao,Yoshida ^[2] ; Takuro,Ishiguro ^[3] ; Katsuya,Fujimoto ^[4] ; Junya,Kuroda ^[5] ; Toshiki,Uchida ^[6] ; Ryusuke,Yamamoto ^[7] ; Yoshiaki,Ogawa ^[8] ; Yasushi,Hiramatsu ^[9] ; Toshiro,Ito ^[10] ; Seiichiro,Katagiri ^[11] ; Tomonori,Nakazato ^[12] ; Kazumi,Suzukawa ^[13] ; Kenzo,Kinami ^[13] ; Mi,Zhou ^[14] ; Eiju,Negoro ^[15]

作者单位： Tohoku University Hospital, Sendai, Japan. ^[1] NHO Shikoku Cancer Center, Matsuyama, Japan. ^[2] Niigata Cancer Center Hospital, Niigata, Japan. ^[3] NHO Hokkaido Cancer Center, Sapporo, Japan. ^[4] Kyoto Prefectural University of Medicine, Kyoto, Japan. ^[5] Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan. ^[6] Kobe City Medical Center General Hospital, Kobe, Japan. ^[7] Tokai University Hospital, Tokyo, Japan. ^[8] Japanese Red Cross Society Himeji Hospital, Himeji, Japan. ^[9] NHO Matsumoto Medical Center, Matsumoto, Japan. ^[10] Tokyo Medical University Hospital, Tokyo, Japan. ^[11] Yokohama Municipal Citizen's Hospital, Yokohama, Japan. ^[12] Incyte Biosciences Japan G.K., Tokyo, Japan. ^[13] Incyte Corporation, Wilmington, Delaware, USA. ^[14] University of Fukui, Fukui, Japan. ^[15]

关键词 follicular lymphoma non‐Hodgkin lymphoma objective response rate parsaclisib phosphatidylinositol 3‐kinase